GB1586466A – Diphenyl methane derivatives
– Google Patents
GB1586466A – Diphenyl methane derivatives
– Google Patents
Diphenyl methane derivatives
Download PDF
Info
Publication number
GB1586466A
GB1586466A
GB4268176A
GB4268176A
GB1586466A
GB 1586466 A
GB1586466 A
GB 1586466A
GB 4268176 A
GB4268176 A
GB 4268176A
GB 4268176 A
GB4268176 A
GB 4268176A
GB 1586466 A
GB1586466 A
GB 1586466A
Authority
GB
United Kingdom
Prior art keywords
formula
ethyl
compound
hydrogen
hydroxy
Prior art date
1977-10-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4268176A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1977-10-12
Filing date
1977-10-12
Publication date
1981-03-18
1977-10-12
Application filed by Lilly Industries Ltd
filed
Critical
Lilly Industries Ltd
1977-10-12
Priority to GB4268176A
priority
Critical
patent/GB1586466A/en
1981-03-18
Publication of GB1586466A
publication
Critical
patent/GB1586466A/en
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
C07C37/0555—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group being esterified hydroxy groups
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
C07C37/20—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms using aldehydes or ketones
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
C07C39/24—Halogenated derivatives
C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
C07C41/01—Preparation of ethers
C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
C07C41/01—Preparation of ethers
C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
C07C41/01—Preparation of ethers
C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C43/00—Ethers; Compounds having groups, groups or groups
C07C43/02—Ethers
C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C43/00—Ethers; Compounds having groups, groups or groups
C07C43/02—Ethers
C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
Description
(54) DIPHENYL METHANE DERIVATIVES
(71) We, LILLY INDUSTRIES
LIMITED, a British Company of Lilly
House, Hanover Square, London W1R OPA, England, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- This invention relates to a class of novel diphenyl methane derivatives, to methods of preparing such derivatives, and to pharmaceutical formulations containing such derivatives.
2 – Hydroxy – 5 – methylbenzhydrol has been described by Moerhle and Miller,
Monatsh. Chem., 1974, 105(6), 1151-63 (C.A. 83, 9711d). However no utility and in particular no pharmacological activity, is disclosed therein for this compound.
According to the present invention there is provided a diphenyl methane derivative of formula (I):
wherein R’ is hydrogen, C14 alkyl or C25 acyl; R2, R3 and R4 are selected from hydrogen, methyl and ethyl, at least one being other than hydrogen; Y is -OH, C14 alkoxy or C25 acyloxy; and Ar is a phenyl group optionally substituted by from one to three groups selected from halogen, methyl, carboxy, -COOR5, nitro, and trifluoromethyl, R5 being C14 alkyl, or a pharmaceutically acceptable salt thereof provided that when R’, R2 and R3 are all hydrogen, Y is -OH and Ar is phenyl, R4 is ethyl.
Preferably R’ is hydrogen or C14 alkyl, Y is -OH or C14 alkoxy, and Ar is phenyl optionally substituted by from one to three groups selected from halogen, methyl and nitro.
The invention also provides a pharmaceutical formulation containing an active ingredient in association with a pharmaceutically acceptable carrier therefor, the active ingredient being a compound of formula (I) as hereinbefore defined or, additionally, 2-hydroxy-5methylbenzhydrol, and a method of preparing such a pharmaceutical formulation which comprises bringing a compound of formula (I) as hereinbefore defined or 2-hydroxy-5-methylbenzhydrol into association with a pharmaceutically acceptable carrier therefor.
Further in accordance with this invention there is provided a method of treating a non-human animal suffering from or susceptible to an allergic condition, and particularly a method of treating immediate hypersensitivity diseases such as asthma, which comprises administering to said animal a therapeutically effective amount of a compound of formula (I) as hereinbefore defined or 2-hydroxy-5-methylbenzhydrol.
Preferred compounds of formula (I) are those having one or more of the following features:
(a) Y is -OH, (b) Y is -OCH3, (c) R’ is hydrogen,
(d) R1 is -CH3, (e) one of R2, R3 and R4 is ethyl, the
other two being hydrogen,
(f) R3 is ethyl, R2 and R4 being
hydrogen,
(g) R4 is ethyl, R2 and R3 being
hydrogen,
(h) Ar is unsubstituted phenyl,
(i) Ar is phenyl substituted by halogen,
(j) Ar is a 4-fluorophenyl group,
(k) Ar is a 4-chlorophenyl group,
(1) Ar is a 4-methyl group.
Particularly preferred compounds are those having features (a), (c), (e), and (i); (a), (c), (f) and (j); (a), (c), (g) and (k); (a), (d), (e) and (1); (a), (d), (g) and (1); (b), (d), (e) and (i); and (b), (d), (g) and (k).
The present invention also provides a method of preparing a compound of formula (I) as defined above which comprises reacting a compound of formula:
wherein R’ is hydrogen C14 alkyl or C25 acyl, and R2, R3, R4 and Ar are as defined above with LiAIH4 or NaB H4, or with aluminium isopropoxide in isopropanol, to produce a compound of formula (I) in which
Y is -OH, optionally alkylating or acylating this product to give a compound of formula (I) in which Y is C14 alkoxy or C25 acyloxy, and where R’ is C25 acyl, hydrolysing to give a compound of formula (I) in which R’ is hydrogen.
In addition the present invention provides a method of preparing a compound of formula (I) as defined above comprising reacting a compound of formula:
wherein R’, R2, R3 and R4 are as defined above with an organometallic compound of formula:
Ar Z wherein Ar is as defined above and Z is a cationic group selected from alkali metal ions, alkaline earth metal ions and a group of formula -MgX, where X is chlorine, bromine or iodine, and hydrolysing the resulting organometallic complex, preferably with acid, to give a compound of formula (I) in which Y is -OH. It is preferred for the compound of formula Ar Z to be an organolithium compound of formula ArLi, or a Grignard reagent of formula ArMgBr.
The compounds of the present invention are useful in the prophylactic treatment of immediate hypersensitivity diseases including asthma and in the alleviation of status asthmaticus in humans. The compounds have low toxicity.
The compounds or compositions of the present invention may be administered by various routes and for this purpose may be formulated in a variety of forms. Thus the compounds of compositions may be administered by the oral, rectal and vaginal routes, topically, parenterally e.g. by injection and by continuous or discontinuous intra-arterial infusion, in the form of, for example, tablets, lozenges, sublingual tablets, sachets cachets, elixirs, suspensions, aerosols, ointments, for example, containing from 1 to 10 /” by weight of the active compound in a suitable base, soft and hard gelatin capsules, suppositories, injection solutions and suspensions in physiologically acceptable media, sterile packaged powders absorbed onto a support material for making injection solutions, vaginal pessaries, tampons, creams to be used with vaginal applicators and diaphragms. Advantageous for this purpose, compositions may be provided in dosage unit form, preferably each dosage unit containing from 5 to 500 mg. (from 5.0 to 50 mg. in the case of parenteral administration, from 5.0 to 50 mg. in the case of inhalation and from 25 to 500 mg. in the case of oral or rectal administration) of a compound of formula (I).
Dosages of from 0.5 to 90 mg/kg per day, preferably 2 to 20 mg/kg, of active ingredient may be administered. It will have readily be understood that the amount of the compound or compounds of formula (I) actually to be administered will be determined by a physician, in the light of all the relevant circumstances including the condition to be treated, the choice of compound to be administered and the choice of route of administration and therefore the above preferred dosage range is not intended to limit the scope of the present invention in any way.
In this specification, the expression “dosage unit form” is used as meaning a physically discrete unit containing an individual quantity of the active ingredient, generally in admixture with a pharmaceutical diluent therefor, or otherwise in association with a pharmaceutical carrier, the quantity of the active ingredient being such that one or more units are normally required for a single therapeutic administration or that, in the case of severable units such as scored tablets, at least one fraction such as a half or a quarter of a severable unit is required for a single therapeutic administration.
The formulations of the present invention normally will consist of at least one compound of formula (I) associated with a pharmaceutically acceptable carrier therefor, i.e. mixed with a carrier, or diluted by a carrier, or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper or other container or by a disposable container such as an ampoule. A carrier or diluent may be a solid, semi-solid or liquid material, which serves as a vehicle, excipient or medium for the active therapeutic substance.
Some examples of the diluents or carriers which may be employed in the pharmaceutical compositions of the present invention are lactose, dextrose, sucrose, sorbitol, mannitol, propylene glycol, liquid paraffin, white soft paraffin, kaolin, fumed silicon dioxide, microcrystalline cellulose, calcium silicate, silica, polyvinylpyrrolidone, cetostearyl alcohol, starch, modified starches, gum acacia, calcium phosphate, cocoa butter, ethoxylated esters, oil of theobroma, arachis oil, alginates, tragacanth, galatin, syrup B.P., methyl cellulose, polyoxyethylene sorbitan monolaurate, ethyl lactate, methyl and propyl hydroxybenzoate, sorbitan trioleate, sorbitan sesquioleate and oleyl alcohol and propellants such as trichloro-monofluoromethane, dichloro-difluoro-methane and dichlorotetrafluoroethane. In the case of tablets, a lubricant may be incorporated to prevent sticking and binding of the powdered ingredients in the dies and on the punch of the tabletting machine. For such purpose there may be employed for instance aluminium, magnesium or calcium stearates, talc or mineral oil.
The invention will be further understood from the following examples.
EXAMPLE 1
2-Hydroxy-4-ethyl-4′-fluorobenzhydrol (a) 2-Acetoxy4-ethyl-4′-fluorobenzophenone
To 2 – hydroxy – 4 – ethyl – 4′ – fluorobenzophenone (5 g, 2.05x 10-2 mol) was added acetic anhydride in excess, and the mixture was refluxed for 5 hours. The excess acetic anhydride was evaporated off, 2N sodium hydroxide (10 ml, 2×10-2 mol) was added and the mixture was extracted with chloroform and dried (over magnesium sulphate). The chloroform solution was filtered and evaporated to leave 2 acetoxy – 4 – ethyl – 4′ – fluoro benzophenone (1.8g, 30%) as an oil which solidified on standing, mp 57-580C.
(b) 2-Hydroxy-4-ethyl-4!-fluorobenzhydrol
The product of step (a) (3g, 1.05×10-2 mol) in ether (20 ml) was added to a stirred suspension of lithium aluminium hydride (0.5g, 1.32×10-2 mol) in refluxing ether (50 ml) over the course of 15 minutes. The mixture was refluxed for a further 30 minutes, cooled and treated with water (0.5 ml), SN sodium hydroxide (0.5 ml), and more water (1.5 ml). When effervescence had ceased the ether fraction was separated, dried (over magnesium sulphate), filtered and evaporated to give the title product which was recrystallised from n-hexane as white needles (0.95g, 29%), mp 94–950C.
EXAMPLE 2
2-Hydroxy-5-ethyl-4′-chlorobenzhydrol
This product was prepared using lithium aluminium hydride as in Example l(b), except that the reaction mixture was processed by adding 2N hydrochloric acid until the pH of the mixture was 4. The ether fraction was then separated, dried (over magnesium sulphate) filtered and evaporated to give the title product (9.1 g, 93 /n) m.p. 69-710C.
EXAMPLE 3 2-Methoxy-5-ethyl-4′-methylbenzhydrol This product was prepared by the method of Example 2. The product (0.7g, 41 /,) was purified by preparative thin layer chromatography and had mp 57-580C.
EXAMPLE 4
2-Methoxy-5-ethyl-4′-chlorobenzhydrol
Sodium borohydride (0.4g, 0.01 mol) was
added to a stirred solution of 2 – methoxy
5- ethyl – 4′ – chlorobenzophenone (2.75g, 0.01 mol) (b p 15152″C/0.25 mm) (prepared by methylation of 2hydroxy – 5 – ethyl – 4′ – chlorobenzophenone) in isopropyl alcohol (40 ml) and
refluxed for 2+ hours. The solution was treated with 2N hydrochloric acid (5 ml) and filtered. The filtrate was extracted with
ether. The ether fraction was dried (over
magnesium sulphate) filtered, and
evaporated. The residue was recrystallised from aqueous methanol and further purified by preparative thin layer chromatography to give the pure title product (0.78g 28%, mp 71-730C.
EXAMPLE 5 (2-Methoxy-5-ethylphenyl) (4
chlorophenyl)methoxymethane 2 – Methoxy – 5 – ethyl – 4′ – chlorobenzhydrol (3g, 0.011 mol) was treated with
60% hydrogen bromide solution (20 ml) and
the mixture was refluxed gently for 30
minutes. The mixture was then cooled, water was added, and the solution was
extracted with chloroform. The chloroform
extract was washed with 10% sodium
carbonate solution, dried (over magnesium
sulphate), filtered and evaporated to give
(2 – methoxy – 5 – ethylphenyl) (4 – chloro
phenyl) bromomethane as an orange-brown
oil (3.63g).
This oil was dissolved in methanol and the
solution was added with stirring to a
solution of sodium hydroxide (0.8g, 0.02
mol) in methanol (30 ml). The solution was refluxed for 1+ hours, cooled, acidified with dilute hydrochloric acid and extracted with chloroform. The chloroform fraction was dried (over magnesium sulphate), filtered, and evaporated to yield the crude title product as an oil. Two recrystallisations from methanol, with decolourisation using animal charcoal yielded the pure title product in the form of white crystals (0.7g, 22%), mp 48–500C.
EXAMPLE 6
2-Hydroxy-4-ethyl-4′-nitrobenzhydrol
To aluminium isopropoxide (13 g, 0.06 mol) in isopropanol (100 ml) was added 2 hydroxy – 4 – ethyl – 4′ – nitrobenzophenone (10.8g, 0.04 mol). The mixture was heated and acetone formed by the reaction distilled off. When no further acetone was formed, after about 6 hours, the solvent was evaporated off and the residue hydrolysed with dilute hydrochloric acid. This residue was extracted with ether and the ether extract was then washed with water, dried over magnesium sulphate and evaporated to yield a yellow crystalline product which was purified by column chromatography, eluting with chloroform, to give the pure title product (10g, 77%) mp 107–8″C.
EXAMPLE 7
2-Hydroxy-4-ethyl-benzhydrol
A solution of 2 – hydroxy – 4ethylbenzophenone (9.05g, 0.04 mol) in dry ether (50 ml) was added, with stirring, over a period of 15 minutes to a solution of lithium aluminium hydride (1.5g, 0.04 mol) in dry ether (150 ml) at 100C. The mixture was allowed to warm to room temperature, and, with continued stirring. hydrolysed at 100C with 2N hydrochloric acid. Water was added and the aqueous layer was extracted with ether. The ether solution was dried over magnesium sulphate and the ether evaporated off to yield a viscous oil which was purified by preparative thin layer chromatography using chloroform as eluent to give the title product (1.8g, 20%) n,2’=1.5879.
WHAT WE CLAIM IS:
1. A diphenyl methane derivative of formula (I):
wherein R’ is hydrogen, C14 alkyl or C25 acyl; R2, R3 and R4 are selected from hydrogen, methyl and ethyl, at least one being methyl or ethyl; Y is -OH, C14 alkoxy or C25 acyloxy; and Ar is a phenyl group optionally substituted by from one to three groups selected from halogen, methyl, carboxy, –COOR5, nitro and trifluoromethyl, R5 being C14 alkyl, or a pharmaceutically-acceptable salt thereof, provided that when R’, R2 and R3 are all hydrogen, Y is -OH and Ar is phenyl, R4 is ethyl.
2. A diphenyl methane derivative according to Claim 1 wherein R’ is hydrogen or C14 alkyl, Y is -OH or C14 alkoxy, and Ar is phenyl optionally substituted by from one to three groups selected from halogen, methyl and nitro.
3. A derivative according to Claim 1 or 2 wherein R’ is hydrogen or methyl; one of
R2, R3 and R4 is ethyl, the others being hydrogen; and Ar is phenyl or phenyl singly substituted by chlorine, fluorine, methyl or nitro.
4. A derivative according to any of Claims 1 to 3 wherein R’, R2 and R4 are hydrogen,
R3 is ethyl, Y is -OH and Ar is phenyl, pfluorophenyl, p-chlorophenyl or pnitrophenyl.
5. 2 – Hydroxy – 4 – ethyl – 4′ – fluorobenzhydrol or a pharmaceuticallyacceptable salt thereof.
6. (2 – Methoxy – 5 – ethylphenyl)(4 chlorophenyl) methoxymethane.
7. A method of preparing a diphenyl methane derivative of formula (I) as defined in any of Claims 1 to 6 which comprises reacting a compound of formula
wherein R’, R2, R3, R4 and Ar are as defined
in any of Claims 1 to 6, with Li Al H4 or Na
BH4, or with aluminium isopropoxide in
isopropanol, to produce a compound of
formula (I) in which Y is -OH, and
optionally alkylating or acylating this
product to give a compuond of formula (I)
in which Y is C14 alkoxy or C25 acyloxy,
and optionally hydrolysing a compound of
formula (I) in which R1 is C2 acyl to give a
compound of formula (I) in which R’ is
hydrogen.
8. A method of preparing a diphenyl
methane derivative of formula (I) as defined
in any of Claims 1 to 6 which comprises
reacting a compound of formula
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (14)
**WARNING** start of CLMS field may overlap end of DESC **.
dilute hydrochloric acid and extracted with chloroform. The chloroform fraction was dried (over magnesium sulphate), filtered, and evaporated to yield the crude title product as an oil. Two recrystallisations from methanol, with decolourisation using animal charcoal yielded the pure title product in the form of white crystals (0.7g, 22%), mp 48–500C.
EXAMPLE 6
2-Hydroxy-4-ethyl-4′-nitrobenzhydrol
To aluminium isopropoxide (13 g, 0.06 mol) in isopropanol (100 ml) was added 2 hydroxy – 4 – ethyl – 4′ – nitrobenzophenone (10.8g, 0.04 mol). The mixture was heated and acetone formed by the reaction distilled off. When no further acetone was formed, after about 6 hours, the solvent was evaporated off and the residue hydrolysed with dilute hydrochloric acid. This residue was extracted with ether and the ether extract was then washed with water, dried over magnesium sulphate and evaporated to yield a yellow crystalline product which was purified by column chromatography, eluting with chloroform, to give the pure title product (10g, 77%) mp 107–8″C.
EXAMPLE 7
2-Hydroxy-4-ethyl-benzhydrol
A solution of 2 – hydroxy – 4ethylbenzophenone (9.05g, 0.04 mol) in dry ether (50 ml) was added, with stirring, over a period of 15 minutes to a solution of lithium aluminium hydride (1.5g, 0.04 mol) in dry ether (150 ml) at 100C. The mixture was allowed to warm to room temperature, and, with continued stirring. hydrolysed at 100C with 2N hydrochloric acid. Water was added and the aqueous layer was extracted with ether. The ether solution was dried over magnesium sulphate and the ether evaporated off to yield a viscous oil which was purified by preparative thin layer chromatography using chloroform as eluent to give the title product (1.8g, 20%) n,2’=1.5879.
WHAT WE CLAIM IS:
1. A diphenyl methane derivative of formula (I):
wherein R’ is hydrogen, C14 alkyl or C25 acyl; R2, R3 and R4 are selected from hydrogen, methyl and ethyl, at least one being methyl or ethyl; Y is -OH, C14 alkoxy or C25 acyloxy; and Ar is a phenyl group optionally substituted by from one to three groups selected from halogen, methyl, carboxy, –COOR5, nitro and trifluoromethyl, R5 being C14 alkyl, or a pharmaceutically-acceptable salt thereof, provided that when R’, R2 and R3 are all hydrogen, Y is -OH and Ar is phenyl, R4 is ethyl.
2. A diphenyl methane derivative according to Claim 1 wherein R’ is hydrogen or C14 alkyl, Y is -OH or C14 alkoxy, and Ar is phenyl optionally substituted by from one to three groups selected from halogen, methyl and nitro.
3. A derivative according to Claim 1 or 2 wherein R’ is hydrogen or methyl; one of
R2, R3 and R4 is ethyl, the others being hydrogen; and Ar is phenyl or phenyl singly substituted by chlorine, fluorine, methyl or nitro.
4. A derivative according to any of Claims 1 to 3 wherein R’, R2 and R4 are hydrogen,
R3 is ethyl, Y is -OH and Ar is phenyl, pfluorophenyl, p-chlorophenyl or pnitrophenyl.
5. 2 – Hydroxy – 4 – ethyl – 4′ – fluorobenzhydrol or a pharmaceuticallyacceptable salt thereof.
6. (2 – Methoxy – 5 – ethylphenyl)(4 chlorophenyl) methoxymethane.
7. A method of preparing a diphenyl methane derivative of formula (I) as defined in any of Claims 1 to 6 which comprises reacting a compound of formula
wherein R’, R2, R3, R4 and Ar are as defined
in any of Claims 1 to 6, with Li Al H4 or Na
BH4, or with aluminium isopropoxide in
isopropanol, to produce a compound of
formula (I) in which Y is -OH, and
optionally alkylating or acylating this
product to give a compuond of formula (I)
in which Y is C14 alkoxy or C25 acyloxy,
and optionally hydrolysing a compound of
formula (I) in which R1 is C2 acyl to give a
compound of formula (I) in which R’ is
hydrogen.
8. A method of preparing a diphenyl
methane derivative of formula (I) as defined
in any of Claims 1 to 6 which comprises
reacting a compound of formula
wherein R1, R2, R3 and R4 are as defined in any of Claims 1 to 6 with an organometallic compound of formula:
ArZ wherein Ar is as defined in any of Claims 1 to 6 and Z is a cationic group selected from alkali metal ions, alkaline earth metal ions and a group of formula -MgX, where X is chlorine, bromine or iodine, and hydrolysing the resulting organometallic complex, preferably with acid, to give a compound of formula (I) in which Y is -OH, and optionally alkylating or acylating to give a compound of formula (I) in which Y is C14 alkoxy or C25 acyloxy.
9. A method according to Claim 7 substantially as hereinbefore described in any one of the Examples.
10. A diphenyl methane derivative as defined in Claim 1 whenever prepared by a method according to any of Claims 7 to 9.
11. A diphenyl methane derivative as defined in Claim 1 substantially as hereinbefore described in any one of the
Examples.
12. A pharmaceutical formulation comprising a diphenyl methane derivative according to any of Claims l to 6, 10 and 11 or 2 – hydroxy – 5 – methylbenzhydrol in association with a pharmaceuticallyacceptable carrier therefor.
13. A method of preparing a pharmaceutical formulation which comprises bringing a diphenyl methane derivative according to any of Claims 1 to 6, 10 and 11 or 2 – hydroxy – 5 – methylbenzhydrol into association with a pharmaceutically-acceptable carrier therefor.
14. A method of treating non-human animals which comprises administering to said animal a therapeutically effective amount of a compound of formula I as defined in claim 1 or 2 – hydroxy – 5 methylbenzhydrol.
GB4268176A
1977-10-12
1977-10-12
Diphenyl methane derivatives
Expired
GB1586466A
(en)
Priority Applications (1)
Application Number
Priority Date
Filing Date
Title
GB4268176A
GB1586466A
(en)
1977-10-12
1977-10-12
Diphenyl methane derivatives
Applications Claiming Priority (1)
Application Number
Priority Date
Filing Date
Title
GB4268176A
GB1586466A
(en)
1977-10-12
1977-10-12
Diphenyl methane derivatives
Publications (1)
Publication Number
Publication Date
GB1586466A
true
GB1586466A
(en)
1981-03-18
Family
ID=10425507
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
GB4268176A
Expired
GB1586466A
(en)
1977-10-12
1977-10-12
Diphenyl methane derivatives
Country Status (1)
Country
Link
GB
(1)
GB1586466A
(en)
Cited By (2)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
FR2540103A1
(en)
*
1983-01-28
1984-08-03
Debat Lab
New benzhydrol derivatives, use in therapeutics and process of preparation
EP0489670A1
(en)
*
1990-12-06
1992-06-10
Rhone-Poulenc Agrochimie
2,6 Alkoxyphenyl alkylketone and herbicidal derivatives
1977
1977-10-12
GB
GB4268176A
patent/GB1586466A/en
not_active
Expired
Cited By (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
FR2540103A1
(en)
*
1983-01-28
1984-08-03
Debat Lab
New benzhydrol derivatives, use in therapeutics and process of preparation
EP0489670A1
(en)
*
1990-12-06
1992-06-10
Rhone-Poulenc Agrochimie
2,6 Alkoxyphenyl alkylketone and herbicidal derivatives
FR2670205A1
(en)
*
1990-12-06
1992-06-12
Rhone Poulenc Agrochimie
2,6-ALKOXYPENYL ALKYLCETONE AND DERIVATIVES HERBICIDES.
Similar Documents
Publication
Publication Date
Title
AU607203B2
(en)
1991-02-28
Improvements in or relating to leukotriene antagonists
EP0253500B1
(en)
1991-02-27
Acylanilide derivatives
US4317915A
(en)
1982-03-02
Novel thiophene derivatives
EP0047536B1
(en)
1984-06-27
Substituted propylamines
JPS5811850B2
(en)
1983-03-04
1-oxo-2,2-dithicane-5-indanyloxy
US3649679A
(en)
1972-03-14
Substituted phenylalkanoic acid derivatives ii
US4992430A
(en)
1991-02-12
Anti-bacterial compositions comprising a substituted bis-(4-aminophenyl)-sulfone and a dihydro-folic acid reductase
US4088773A
(en)
1978-05-09
Acylamino derivatives
US5110831A
(en)
1992-05-05
Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
US4428963A
(en)
1984-01-31
Novel thiophene derivatives
US4057641A
(en)
1977-11-08
Method of treating inflammation with 2-(2,3-dihydro-2-isopropyl-4-oxo-4H-1-benzopyran-6-yl)propionic acid
US4234742A
(en)
1980-11-18
Bis-(aryloxycarboxylic acid) compounds
US4749798A
(en)
1988-06-07
Fluoro coumarins as antilymphoedema agents
GB2092144A
(en)
1982-08-11
Novel indanyl derivaitves
EP0074170B1
(en)
1985-10-16
Chroman compounds, process for producing them and pharmaceutical compositions containing them
US4539326A
(en)
1985-09-03
5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents
US4282360A
(en)
1981-08-04
7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
US3671580A
(en)
1972-06-20
Substituted biphenyl acetic acids and ester derivatives thereof
GB1586466A
(en)
1981-03-18
Diphenyl methane derivatives
US4252818A
(en)
1981-02-24
Novel benzopyran derivatives
EP0055068A1
(en)
1982-06-30
Quinolone derivatives and their use as pharmaceuticals
GB2131431A
(en)
1984-06-20
Benzofuran derivatives
US4977181A
(en)
1990-12-11
Tromethamine salt of 1-methyl-beta-oxo-alpha-(phenylcarbamoyl)-2-pyrrolepropionitrile
US4230716A
(en)
1980-10-28
Treating immediate hypersensitivity conditions with 3,5-disubstituted hydantoin derivatives
US4778925A
(en)
1988-10-18
New benzoic acid derivatives, as well as processes for their production and their use as pharmaceuticals
Legal Events
Date
Code
Title
Description
1981-06-03
PS
Patent sealed
1984-06-13
PCNP
Patent ceased through non-payment of renewal fee
